AOD9604Research compoundARA-290Phase 2ArgirelineResearch compoundBPC-157Research compoundCagrilintidePhase 3CJC-1295Research compoundDihexaPreclinicalEpitalonResearch compoundGHK-CuResearch compoundGHRP-2Research compoundGHRP-6Research compoundHexarelinResearch compoundHumaninPreclinicalIpamorelinResearch compoundKPVResearch compoundLiraglutideApprovedLL-37PreclinicalMatrixylResearch compoundMelanotan IIResearch compoundMOTS-cPreclinicalPT-141ApprovedRetatrutidePhase 3SelankResearch compoundSemaglutideApprovedSemaxResearch compoundSermorelinResearch compoundSS-31Phase 3SurvodutidePhase 3TB-500Research compoundTesamorelinApprovedThymosin Alpha-1ApprovedTirzepatideApprovedAOD9604Research compoundARA-290Phase 2ArgirelineResearch compoundBPC-157Research compoundCagrilintidePhase 3CJC-1295Research compoundDihexaPreclinicalEpitalonResearch compoundGHK-CuResearch compoundGHRP-2Research compoundGHRP-6Research compoundHexarelinResearch compoundHumaninPreclinicalIpamorelinResearch compoundKPVResearch compoundLiraglutideApprovedLL-37PreclinicalMatrixylResearch compoundMelanotan IIResearch compoundMOTS-cPreclinicalPT-141ApprovedRetatrutidePhase 3SelankResearch compoundSemaglutideApprovedSemaxResearch compoundSermorelinResearch compoundSS-31Phase 3SurvodutidePhase 3TB-500Research compoundTesamorelinApprovedThymosin Alpha-1ApprovedTirzepatideApproved
Vendor Standard / United States
75B

Polaris Peptides

polarispeptides.com

Polaris posts dated batch COAs from named independent labs (AccuMark and Janoshik, HPLC-MS), and they show both the latest and previous results per product, which is rare. They're also unusually honest about actual content versus label: one product literally says 'tested at 7.5mg' on a 5mg vial. Full catalog and pricing are out in the open.

Score Breakdown

Testing transparency17/20

Named labs AccuMark Labs and Janoshik; HPLC-MS; latest + previous results per product.

COA quality14/15

Dated, batch-specific reports with full PDF; purity and history shown.

Batch traceability12/15

Latest + previous dated lab reports per product (e.g., 99.03% 2026-06-17; 99.82% 2025-05-14).

Supplier consistency8/15

Independent Finnrick data (97 samples) shows quality swings by product: tirzepatide A, but retatrutide D across 26 samples, with BPC-157 and semaglutide middling.

Community reputation5/10

Not on reptides; Trustpilot 3.9/5 across 24 reviews, distinctly bimodal (people love it or strongly dislike it).

Support / fulfillment7/10

Phone + email, money-back guarantee, bulk pricing.

Marketing integrity8/10

Discloses actual tested content (e.g., DSIP 5mg label 'tested at 7.5mg').

Evidence quality4/5

Named third-party labs with full PDFs; verified via authenticated session.

Positive Signals

  • +Named labs AccuMark + Janoshik
  • +Dated batch COAs with latest+previous history
  • +Finnrick A-rated tirzepatide and PT-141
  • +Transparent about actual tested content

Trust Concerns

Their own paperwork is good, but independent testing tells a more mixed story. Finnrick ran 97 samples and their tirzepatide grades an A while their retatrutide grades a D across 26 samples, which is too many to write off as one bad lot. BPC-157 and semaglutide land in the middle. Trustpilot is bimodal too (3.9 across 24, people either love it or don't). The honest 'tested at 7.5mg' labeling is a plus, but I'd stick to their A-rated products and independently test anything reta.

  • !Independent Finnrick testing (97 samples) grades their retatrutide a D across 26 samples, a systemic issue on that product line rather than one bad lot
  • !Trustpilot is bimodal (3.9/5 over 24 reviews)
  • !Label-vs-content variance disclosed (e.g., 5mg vial 'tested at 7.5mg'), so dosing isn't exactly what the label says

Researcher Notes

  • Named labs AccuMark + Janoshik with dated COAs
  • Finnrick: tirzepatide A, but retatrutide D across 26 samples
  • Trustpilot 3.9/5, bimodal
  • Discloses actual tested mg vs label
  • Quality varies a lot by product, so check the specific compound

Evidence Log

DSIP COAs: AccuMark Labs 99.03% (2026-06-17), Janoshik 99.82% (2025-05-14), 99.97% (2024-06-04); HPLC-MS; latest+previous reports

Finnrick (97 samples): tirzepatide A (8.8/10), retatrutide D across 26 samples, BPC-157 and semaglutide C; Trustpilot 3.9/5, bimodal

Evidence accessed 2026-06-26.